{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:05:42Z","timestamp":1777572342569,"version":"3.51.4"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Although smallpox has been eradicated, the United States government considers it a \u201cmaterial threat\u201d and has funded the discovery and development of potential therapeutic compounds. As reported here, the human efficacious dose for one of these compounds, ST-246, was determined using efficacy studies in nonhuman primates (NHPs), together with pharmacokinetic and pharmacodynamic analysis that predicted the appropriate dose and exposure levels to provide therapeutic benefit in humans. The efficacy analysis combined the data from studies conducted at three separate facilities that evaluated treatment following infection with a closely related virus, monkeypox virus (MPXV), in a total of 96 NHPs. The effect of infection on ST-246 pharmacokinetics in NHPs was applied to humans using population pharmacokinetic models. Exposure at the selected human dose of 600 mg is more than 4-fold higher than the lowest efficacious dose in NHPs and is predicted to provide protection to more than 95% of the population.<\/jats:p>","DOI":"10.1128\/aac.00959-12","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T04:21:37Z","timestamp":1355804497000},"page":"1136-1143","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacokinetic and Pharmacodynamic Modeling To Determine the Dose of ST-246 To Protect against Smallpox in Humans"],"prefix":"10.1128","volume":"57","author":[{"given":"Janet M.","family":"Leeds","sequence":"first","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederique","family":"Fenneteau","sequence":"additional","affiliation":[{"name":"Pharsight Consulting Services, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie H.","family":"Gosselin","sequence":"additional","affiliation":[{"name":"Pharsight Consulting Services, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad-Samer","family":"Mouksassi","sequence":"additional","affiliation":[{"name":"Pharsight Consulting Services, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nastya","family":"Kassir","sequence":"additional","affiliation":[{"name":"Pharsight Consulting Services, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Marier","sequence":"additional","affiliation":[{"name":"Pharsight Consulting Services, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Chen","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Grosenbach","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie E.","family":"Frimm","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kady M.","family":"Honeychurch","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarasvech","family":"Chinsangaram","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthakumar R.","family":"Tyavanagimatt","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis E.","family":"Hruby","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[{"name":"SIGA Technologies, Corvallis, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb135034.x"},{"key":"e_1_3_2_3_2","volume-title":"Smallpox and its eradication","author":"Fenner F","year":"1988","unstructured":"FennerF HendersonDA AristaI JerzekZ LadnyiID. 1988. The clinical features of smallpox. Smallpox and its eradication. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_2_4_2","volume-title":"Smallpox","author":"Dixon CW","year":"1962","unstructured":"DixonCW. 1962. Smallpox. J. & A. Churchill Ltd., London, United Kingdom."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.361"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01596-08"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.03.005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.76.768"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02173-10"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.20.13139-13149.2005"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00762-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00021-09"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405954101"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024832"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01044-08"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2011.07.013"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.10.063"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4433-4443.2004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2217\/17460913.2.1.17"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01689-09"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023237"},{"key":"e_1_3_2_23_2","volume-title":"Guidance for industry: bioanalytical method validation","author":"FDA","year":"2001","unstructured":"FDA. 2001. Guidance for industry: bioanalytical method validation. FDA, Washington, DC."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00904-12"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00001"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"e_1_3_2_27_2","unstructured":"FDA. 2005. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. FDA Washington DC."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04011.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/507571"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810603"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.106"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00959-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00959-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:13:59Z","timestamp":1645481639000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00959-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1128\/AAC.00959-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.00959-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"2012-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-12-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}